News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
21 Jun 2026
byStephen Padilla
Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.








